Serina Therapeutics, Inc. (SER) - 10-Q Summary
Business Context and Reporting Period
Company: Serina Therapeutics, Inc.
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A clinical-stage biotechnology company developing drug candidates for neurological diseases using its proprietary POZ drug delivery technology. The lead candidate, SER-252 (POZ-apomorphine), is in Phase 1b clinical trials for advanced Parkinson's disease.
Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern, as current cash resources are not expected to fund operations for the next 12 months.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenues | $0 | $130 |
| Net Loss | $(13,254) | $(11,284) |
| Net Loss Attributable to Common Stockholders | $(15,867) | $(11,378) |
| Net Loss Per Share (Basic & Diluted) | $(1.11) | $(1.15) |
| Operating Cash Flow | $(11,252) | $(8,072) |
| Financing Cash Flow | $31,259 | $10,487 |
| Cash and Cash Equivalents (End of Period) | $23,024 | $6,041 |
| Total Liabilities | $7,084 | $6,988 |
| Stockholders' Equity | $18,730 | $(37) |
Material Changes vs. Prior Period
- Revenue: No revenue recognized in the current period compared to $130,000 in grant revenue in the prior year period.
- Operating Expenses: Increased by approximately $1.5 million year-over-year for the six-month period. Research and Development (R&D) expenses rose $0.9 million, and General and Administrative (G&A) expenses rose $0.6 million, driven by increased clinical activities, headcount, and legal fees.
- Net Loss: Increased by $1.97 million to $13.3 million, primarily due to higher operating expenses and a $1.6 million loss on the extinguishment of financial commitment assets.
- Liquidity: Cash position improved significantly from $3.1 million at year-end 2025 to $23.0 million at June 30, 2026, following a $21.2 million PIPE financing and $10.2 million in ATM sales.
- Capital Structure: All Series A Convertible Preferred Stock was converted to common stock. The 2025 Convertible Note was amended to remove future borrowing obligations.
Guidance, Outlook, and Risks
- Capital Needs: The Company explicitly states it will require additional financing to continue operations and advance clinical trials. Failure to secure funding could force delays or termination of programs.
- Clinical Progress: The FDA cleared the IND for SER-252 in January 2026 after a temporary clinical hold. The first patient was dosed in February 2026 in the Phase 1b study.
- Ownership Concentration: Following the March 2026 PIPE, Dr. Gregory H. Bailey (Board Member) beneficially owns approximately 41% of the common stock, and Juvenescence owns approximately 17%. This concentration may influence corporate control.
- Listing Compliance: The Company is operating under an accepted plan to regain compliance with NYSE American listing standards regarding stockholders' equity. While equity improved to $18.7 million, continued compliance is subject to review.
- Unusual Items: The financial results include significant non-cash items, including a $1.6 million loss on extinguishment of financial commitment assets and a $1.4 million gain from the settlement of tranche liability related to the PIPE financing.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure and current burn rate of ~$11.3M over six months.
- PIPE Terms: Review the terms of the redeemable warrants issued in the March 2026 PIPE, specifically the $10.00 call price and redemption triggers tied to clinical milestones.
- Ownership Dilution: Assess the impact of the 41% ownership by Dr. Bailey and the potential exercise of outstanding warrants on future dilution and voting control.
- Convertible Note Status: Confirm the remaining balance and interest obligations of the $5.0 million tranche of the 2025 Convertible Note that remains outstanding.
- Listing Status: Monitor future filings for updates on the NYSE American compliance plan and any risk of delisting if equity levels fluctuate.